USPTO serial 79435823
Reviewed by CopyMark Law Group
Status 686 means your mark is published in the USPTO Official Gazette and in the 30-day opposition period. If no opposition is filed, prosecution typically continues toward registration or a Notice of Allowance. Monitor the opposition window. After it closes, watch for Notice of Allowance (intent-to-use) or registration (use-based).
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Christopher R. Butler
Christopher R. Butler HAHN LOESER & PARKS LLP200 Public Square, Suite 2800Cleveland, OH 44114United States| Class | Description | Status | First use |
|---|---|---|---|
| 009 | Scientific apparatus and instruments, namely, data processing equipment, laboratory robots, and autonomous robotic systems for scientific and laboratory use; research apparatus and instruments, namely, pharmaceutical and scientific research equipment for use in the development and manufacturing of pharmaceutical products; measuring apparatus and instruments, namely, electronic apparatus for measuring physical, chemical, and biological parameters in pharmaceutical and chemical manufacturing processes; detecting apparatus and instruments, namely, electronic apparatus for detecting physical, chemical, and biological parameters in pharmaceutical and chemical manufacturing processes; testing apparatus and instruments, namely, quality control robots, electronic apparatus, and machines for testing pharmaceutical products; inspecting apparatus and instruments, namely, quality control robots, electronic apparatus, and machines for inspecting pharmaceutical products; electronic manufacturing controls systems for industrial and pharmaceutical manufacturing machines; electronic testing and quality control equipment, namely, sensing and testing devices for measurement and quality control of pharmaceutical products; apparatus and instruments for recording, transmitting, reproducing or processing sound, images or data; recorded multimedia files containing text, audio and video relating to artificial intelligence, machine learning, collaborative robotics and automated systems in the field of pharmaceutical development, manufacture and supply; recorded multimedia files containing text, audio, and video relating to artificial intelligence, machine learning, collaborative robotics, and automated systems in the field of pharmaceutical development, pharmaceutical manufacture, and pharmaceutical supply; downloadable multimedia files containing text, audio and video relating to the field of chemistry, manufacturing, and controls, pharmaceutical development, manufacture, and supply; downloadable multimedia files containing text, audio, and video in the field of chemistry, manufacturing, and controls, pharmaceutical development, pharmaceutical manufacture, and pharmaceutical supply; downloadable computer software incorporating artificial intelligence and machine learning for the optimisation of chemical and pharmaceutical development and manufacturing processes; downloadable computer software incorporating artificial intelligence and machine learning for the optimisation of chemical and pharmaceutical development processes and chemical and pharmaceutical manufacturing processes; computers and computer peripheral devices; downloadable computer software for data management, scientific and industrial process control, quality assurance in the field of pharmaceutical development, pharmaceutical manufacture, and pharmaceutical supply, and regulatory compliance auditing; downloadable computer software for managing business or scientific processes; downloadable computer-aided manufacturing (CAM) software for pharmaceutical use; downloadable computer aided manufacturing (CAM) software for use in pharmaceutical development, pharmaceutical manufacture, and pharmaceutical design; downloadable scientific and industrial process controlling software | ACTIVE | — |
| 041 | Educational services, namely, conducting classes, seminars, conferences, and workshops in the field of chemistry, manufacturing, and controls, pharmaceutical development, pharmaceutical manufacture, and pharmaceutical supply; providing of training in the field of chemistry, manufacturing, and controls, pharmaceutical development, pharmaceutical manufacture, and pharmaceutical supply; manufacturing training services; education services, namely, conducting classes, seminars, conferences and workshops in the field of chemistry; training services in the field of chemistry; education services, namely, conducting classes, seminars, conferences, and workshops in the field of chemistry processes and controls; training services in the field of chemistry processes and controls; education, namely, conducting classes, seminars, conferences, and workshops relating to manufacture of pharmaceuticals; training services relating to manufacture of pharmaceuticals | ACTIVE | — |
| 042 | Scientific and technological services, namely, scientific and technological research, analysis, and testing in the field of chemistry, manufacturing and controls; scientific research and design relating to the aforementioned services; research and development services in the field of pharmaceutical development, pharmaceutical manufacture, and pharmaceutical supply; research and development services in the field of chemistry; scientific research relating to chemistry; scientific research for medical purposes in the field of pharmaceutical development, pharmaceutical manufacture, and pharmaceutical supply; medical research services; medical and pharmacological research services; chemistry consultation services; consultancy relating to pharmaceutical research and development; consultancy and information service relating to research and development of pharmaceutical products; industrial analysis, namely, analysis of pharmaceutical products and pharmaceutical development processes, and pharmaceutical manufacturing processes; industrial research in the field of pharmaceutical development, pharmaceutical manufacturing, and pharmaceutical supply; industrial design services; testing services in the field of chemistry, manufacturing, and controls, pharmaceutical development, pharmaceutical manufacture, and pharmaceutical supply; quality authentication services, namely, authenticating pharmaceutical products, pharmaceutical development processes, and pharmaceutical manufacturing processes; quality control services for others; pharmaceutical product quality testing services; product safety testing and consultation; consultancy related to quality control of goods and services; process monitoring for quality assurance in the field of pharmaceutical development, pharmaceutical manufacture, and pharmaceutical supply; design and development of computer hardware and software; providing online non downloadable software for scientific and industrial process control, quality assurance in the field of pharmaceuticals, and regulatory compliance auditing; providing temporary use of non-downloadable software for managing business and scientific processes; providing temporary use of non-downloadable software for industrial process management; computer programming in the pharmaceutical field; development of computer software for computer aided design and computer aided pharmaceutical manufacturing | ACTIVE | — |
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 6, 2026 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Oct 6, 2026 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Sep 30, 2026 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Sep 9, 2026 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Aug 11, 2026 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Aug 11, 2026 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Aug 11, 2026 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 5, 2026 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| Aug 5, 2026 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 5, 2026 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Aug 5, 2026 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Aug 5, 2026 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Feb 26, 2026 | RFNT | REFUSAL PROCESSED BY IB | — |
| Feb 11, 2026 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Feb 11, 2026 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Jan 15, 2026 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Jan 14, 2026 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 6, 2026 | DOCK | ASSIGNED TO EXAMINER | — |
| Nov 3, 2025 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Nov 3, 2025 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Oct 30, 2025 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |